Astra Zeneca announced at the American Heart Association Congress, which closed in Chicago yesterday, data from the DECLARE-TIM trial, aimed at assessing Farxiga (dapagliflozin) on patients with diabetes. The results show that Farxiga significantly reduced (-17%) the risk of hospitalization for heart failure, which is rather common in patients with type-2 diabetes, a condition affecting 425 million people in the world.
AstraZeneca some days ago announced its third quarter 2018 results, which showed signs of recovery for the first time since 2014. Specifically, Farxiga’s sales volume increased by 32% YTD to $994m, that is 6% of the whole group’s revenues. Emerging markets have played a significant role in this: Farxiga’s sales in these countries increased by 57% ($242m).